Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Animal and cell studiesStub

FOXO4-DRI

Senolytic peptide

A peptide made of D-amino acids that disrupts the binding of FOXO4 to p53 in senescent cells, studied in mice.

Reconstitution calculator

At a glance

Animal and cell studies

The published evidence is from animals and cells. Little or nothing is published from controlled trials in people.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals: FOXO4-DRI

    Laboratory and animal work. An animal result is not a result in people.

19
papers on PubMed
9
of them in people
0
randomized trials
5
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on FOXO4-DRI itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of FOXO4-DRI; no amount here is a recommendation.

FOXO4-DRI: on PubMed

What PubMed held for FOXO4-DRI on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

19
papers
9
in humans
0
clinical trials
0
randomized trials
2012: 0 papers122013: 0 papers2014: 0 papers142015: 0 papers2016: 0 papers162017: 3 papers2018: 2 papers182019: 0 papers2020: 1 papers202021: 2 papers2022: 3 papers222023: 2 papers2024: 2 papers242025: 3 papers2026: 4 papers so far26
Papers per year, 2012 to 2026. The most in one year: 4.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells

    StudyLi Y, Zhang C, Cheng H, et al. Experimental gerontology, 2024. PMID 39025385

  2. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

    StudyKong YX, Li ZS, Liu YB, et al. Communications biology, 2025. PMID 39994346

  3. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

    StudyBorn E, Lipskaia L, Breau M, et al. Circulation, 2023. PMID 36515093

  4. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

    StudyZhang C, Xie Y, Chen H, et al. Aging, 2020. PMID 31959736

  5. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice

    StudyLiu Y, Hou Q, Wang R, et al. Naunyn-Schmiedeberg's archives of pharmacology, 2023. PMID 37074394

  6. Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia

    StudyJing X, Jia S, Teng M, et al. American journal of respiratory cell and molecular biology, 2024. PMID 37874230

Search used: ("FOXO4-DRI"[tiab]). Run it on PubMed

Research links

Also in Skin and longevity